European Journal of Molecular & Clinical Medicine

Abstract

Obesity is the lifestyle disorder which is becoming very common with the passage of time due to the unhealthy lifestyle followed by us resulting into fat accumulation and abnormal increase in body weight which ultimately leads to many other fatal diseases. The drugs proposed by FDA for the treatment and management of obesity are administered through different routesto exhibit their effective pharmacological action but these drugs are having either poor solubility or poor permeability due to which an achieving an effective bioavailability is a challenge. Solid lipid nanoparticles are the lipid based nano-carriers which facilitates the drug to reach into the systemic circulation. Solid lipid nanoparticles carry the drug in their lipidic medium increasing the permeability through the phospholipid bilayer. The approach is empowered by articulating from conventional to lipid-based nano-carrier formulation and in addition, specific amendment in the functional components. The enhanced solubility and therefore the bioavailability results into dose reduction which also lowers the risk of side effects due to drug toxicity or due to higher doses.